**Overview**
Zurampic® (lesinurad) is a URAT1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

**Approvable Diagnosis**
1. Hyperuricemia associated with chronic gout refractory to conventional therapies
2. Tophaceous gout (chronic gout with the presence of tophi)

**Coverage Guidelines**
Authorization may be granted for members who are new to AllWays Health Partners and has been stabilized on Zurampic® for an approvable diagnosis excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**Exceptions**
N/A
5. Patient will be prescribed Zurampic® in combination with a xanthine oxidase inhibitor

**Continuation of Therapy**
Reauthorization requires physician documentation of improvement in serum uric acid (sUA) levels.

**Limitations**
1. Approvals will be granted for 6 months
2. The following quantity limits apply:

| Zurampic   | 30 tablets in 30 days |

**References**
6. Krystexxa (pegloticase) [prescribing information]. Lake Forest, IL: Horizon Pharma USA; July 2018
8. Uloric (febuxostat) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America; February 2018.

**Review History**
11/27/17 – Reviewed
11/26/18 – Reviewed in P&T Meeting

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.